fda warning letters compounded semaglutide september 2025 Issues Warnings Against Illegal GLP-1 Marketing FDA COMES FOR NOVO DRAMA.

Warnings Consult with your healthcare practitioner prior to use

This is the single most consequential development for anyone evaluating compounded GLP-1 access right now

While many people experience weight regain after stopping GLP-1 drugs, recent research suggests that exercising while on this medication can promote healthy weight management

GlucoBooster is likely not the right fit for people who: Expect results comparable to prescription GLP-1 medications Are looking for rapid or dramatic weight loss solutions Have medical conditions requiring specific treatment (consult your physician) Are pregnant or nursing (consult your physician before any new supplement) Are currently taking medications that might interact with probiotics (consult your physician) Want a solution backed by large-scale human clinical trials on the finished product What GlucoBooster Is Not To set appropriate expectations: GlucoBooster is not a medication